INT10053

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1992
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 9.14
Pain Relevance 3.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
platelets 3
macrophages 1
leukocytes 1
endothelial cells 1
neurons 1
Paf (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 75 100.00 Very High Very High Very High
dorsal root ganglion 94 99.76 Very High Very High Very High
Inflammation 267 98.24 Very High Very High Very High
cINOD 12 97.56 Very High Very High Very High
Opioid 4 97.24 Very High Very High Very High
ischemia 13 96.16 Very High Very High Very High
Multiple sclerosis 329 95.88 Very High Very High Very High
Potency 10 93.12 High High
cytokine 220 88.72 High High
fibrosis 20 83.40 Quite High
Disease Link Frequency Relevance Heat
Sepsis 99 100.00 Very High Very High Very High
Ganglion Cysts 97 99.76 Very High Very High Very High
INFLAMMATION 311 98.84 Very High Very High Very High
Injury 64 98.80 Very High Very High Very High
Coronary Heart Disease 34 98.24 Very High Very High Very High
Cv Unclassified Under Development 12 96.16 Very High Very High Very High
Adhesions 22 95.92 Very High Very High Very High
Multiple Sclerosis 372 95.88 Very High Very High Very High
Anaerobic Bacterial Infections 2 95.68 Very High Very High Very High
Disease 155 95.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Because the dose of PAF-R antagonists which inhibit endotoxin-induced sepsis are typically more than 10-fold higher than those for PAF released during sepsis, it is suggests that protective effect of PAF antagonist may be related in non-specific inhibition [19].
Localization (released) of PAF associated with antagonist and sepsis
1) Confidence 0.80 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 1.16 Pain Relevance 0.44
Because the dose of PAF-R antagonists which inhibit endotoxin-induced sepsis are typically more than 10-fold higher than those for PAF released during sepsis, it is suggests that protective effect of PAF antagonist may be related in non-specific inhibition [19].
Localization (released) of PAF associated with antagonist and sepsis
2) Confidence 0.75 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 1.26 Pain Relevance 0.46
Carbamyl-PAF (cPAF), an analogue of PAF, is more metabolically stable and capable of maintaining PAF activity for longer durations.
Localization (analogue) of PAF
3) Confidence 0.75 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 0.21 Pain Relevance 0.10
Carbamyl-PAF (cPAF), an analogue of PAF, is more metabolically stable and capable of maintaining PAF activity for longer durations.
Localization (analogue) of Carbamyl-PAF
4) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 0.21 Pain Relevance 0.10
Carbamyl-PAF (cPAF), an analogue of PAF, is more metabolically stable and capable of maintaining PAF activity for longer durations.
Localization (analogue) of cPAF
5) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 0.21 Pain Relevance 0.10
Administration of PAF attenuated LPS-induced organ injury
Localization (Administration) of PAF associated with injury
6) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714981 Disease Relevance 0.44 Pain Relevance 0.27
Studies to elucidate receptor selectivity of PAF continue.
Localization (selectivity) of PAF
7) Confidence 0.64 Published 1997 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 9329049 Disease Relevance 0 Pain Relevance 0.29
PAF may be released from DRG neurons and then activates PAFR expressed in macrophages.
Localization (released) of PAF in neurons associated with dorsal root ganglion
8) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2862737 Disease Relevance 1.11 Pain Relevance 0.75
Platelet activating factor (PAF) is a potent phospholipid released by activated endothelial cells.
Localization (released) of PAF in endothelial cells
9) Confidence 0.19 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 1.32 Pain Relevance 0.09
The explanation was that platelets secreted an inactive form of PAF (de-acetylated) which was re-acetylated by the neutrophils and then thrown back to strongly activate the platelets.
Localization (secreted) of PAF in platelets
10) Confidence 0.17 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 0.31 Pain Relevance 0.11
More specifically, the PAF secreted by the cooperation of platelets and leukocytes would facilitate opening the BBB in the microenvironment, since one of the most prominent actions of PAF is disruption of endothelial junctions [183-186].
Localization (secreted) of PAF in leukocytes
11) Confidence 0.17 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 0.36 Pain Relevance 0.13
Platelet activation induced by co-incubation with neutrophils stimulated by fMLP (fMLP stands for formyl-Met-Leu-Phe) was almost completely prevented by PAFR blockade; and the PAF released in the interaction was greater than the sum produced by platelets or neutrophils alone [182].
Localization (released) of PAF in Platelet
12) Confidence 0.15 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 0.35 Pain Relevance 0.14
This study also confirmed the protective effects of IL-1 in experimental NSAID-gastropathy, and demonstrates that one of the ways the IL-1 may protect the mucosa is through its ability to inhibit the release of proinflammatory mediators (e.g., PAF) and promote the release of antiinflammatory mediators (e.g., nitric oxide).
Localization (release) of PAF associated with inflammation and cinod
13) Confidence 0.11 Published 1992 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 1456666 Disease Relevance 0.32 Pain Relevance 0.33
The release of vasoconstrictor substances, such as thromboxane A2 (TXA2) and platelet activating factor (PAF) by macrophages, which are the predominant inflammatory cells, was proposed to cause transient ischemia and myocytolytic necrosis [8].
Spec (proposed) Localization (release) of PAF in macrophages associated with necrosis, inflammation and ischemia
14) Confidence 0.10 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 1.52 Pain Relevance 0.21
More specifically, the PAF secreted by the cooperation of platelets and leukocytes would facilitate opening the BBB in the microenvironment, since one of the most prominent actions of PAF is disruption of endothelial junctions [183-186].
Localization (secreted) of PAF in platelets
15) Confidence 0.06 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 0.36 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox